In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...

AstraZeneca's strong results boosted the FTSE 100 to a record close, aided by the Bank of England's rate cut. The BoE's ...

(Reuters) -Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

--Best two-day stretch since the two days ending Nov. 11, 2020, when it rose 7.35% --Down 15.77% from its all-time closing high of $87.62 on Aug. 30, 2024 --Up 16.18% from 52 weeks ago (Feb. 8, 2024), ...

A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...

The deal was signed with the Energize programme, a renewable energy purchasing vehicle for pharmeceutical companies.

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...